Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973982 | 0.84 | CYP24A1 (0.35) | ALDH1A1LMNAKDM4EMAPTTBXAS1 | |
| SCHEMBL26597451 | 0.83 | HDAC1 (0.34) | ALDH1A1LMNAKDM4ETBXAS1TSHR | |
| SCHEMBL20511767 | 0.81 | MAOB (0.40) | CYP1A2TBXAS1 | |
| SCHEMBL20511745 | 0.81 | CYP19A1 (0.38) | ALDH1A1LMNACYP1A2CYP3A4TBXAS1 | |
| SCHEMBL20509607 | 0.79 | PDE10A (0.47) | CYP1A2 | |
| SCHEMBL19973543 | 0.79 | SMN1; SMN2 (0.50) | ALDH1A1LMNACYP1A2CYP3A4KDM4E | |
| SCHEMBL20509883 | 0.78 | POLB (0.37) | MEN1KMT2AALDH1A1LMNACYP1A2 | |
| SCHEMBL20510282 | 0.77 | KDM4E (0.48) | ALDH1A1LMNAKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL19974013 | 0.77 | GRM2 (0.36) | ALDH1A1LMNACYP1A2KDM4ESMN1; SMN2 | |
| SCHEMBL19973992 | 0.76 | PDE10A (0.44) | MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
| WO-2018052967-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | DPP4 960/4885GRM5 3087/4885GRM1 3785/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | DPP4 960/4885GRM5 3087/4885GRM1 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.